Daniel T. Lee
FDA investigator
Appears on 1 document from 2026, mostly at sites in New Jersey. Most often cites production record review (21 CFR 211.192).
- 1
- Documents on file
- 3.0
- Observations per 483
- 2026
- First seen
- 2026
- Most recent
What they cite most
From 3 observations- 21 CFR 211.192Production record review1
- 21 CFR 211.22(d)Responsibilities of quality control unit1
- 21 CFR 211.84(b)Testing and approval or rejection of components, drug product containers, and closures1
Activity by year
2026: 1
Where
New Jersey 1
Often inspects with
Is Daniel T. Lee coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2026-04-17 | 483 Novel Laboratories, Inc. d.b.a LupinApr 17, 2026 · Somerset, New Jersey | Somerset, New Jersey | 3 |
About this profile
What does Daniel T. Lee inspect?
Daniel T. Lee appears on 1 document on file covering 1 site, mostly in New Jersey.
What do they cite most often?
21 CFR 211.192 (production record review), followed by 21 CFR 211.22(d) and 21 CFR 211.84(b).
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Daniel T. Lee is dated Apr 17, 2026.